BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
A federal framework would embolden countless companies to dive into the stablecoin market, according to Chronicle Labs ...
As the legal and political landscape surrounding data governance continues to evolve, businesses must adopt agile strategies.
The UK Competition and Markets Authority found that BCD and Amex GBT are the two strongest companies in corporate travel, ...
Data center development is creating enormous demands for power. With few options besides fossil fuels, interest has grown in ...
China’s economy has grown impressively over the past several decades. It is now unquestionably the world’s second largest, and it has become far more innovative than it once was. But it is not nearly ...
Our fair value estimate for Telstra is AUD 4.50 per share. This implies a forward fiscal 2025 enterprise value/EBITDA of 7.7 and a dividend yield of 4.2%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback